Antisense modulation of apolipoprotein B-expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsRosanne M. Crooke, Mark J. Graham, Susan M. Freier
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
Claims36
An antisense compound 12 to 30 nucleobases in length, wherein said antisense compound is fully complementary within the range of nucleotides 5562-5625 of SEQ ID NO:3, and comprises at least one modified sugar moiety.
An antisense compound 20 to 30 nucleobases in length comprising at least 13 contiguous nucleobases of SEQ ID NO:
- 224 and at least one modified sugar moiety, wherein said antisense compound specifically hybridizes to SEQ ID NO:3.
An antisense oligonucleotide consisting of SEQ ID NO:
- 224, wherein nucleobases 1-5 and 16-20 comprise 2′-methoxyethoxy nucleotides, nucleobases 6-15 are 2′-deoxynucleotides, each internucleoside linkage is a phosphorothioate internucleoside linkage, and each cytosine is a 5-methylcytosine.
Dependencies are inferred from the claim text.